🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2022-502362-24-00
Completed Phase II

Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial, ADEM2 study

2022-502362-24-00 · tracked via the Priya Life Science EU tracker
Sponsor
Centre Hospitalier Universitaire De Nice
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Musculoskeletal Diseases
Decision date
17/10/2025
Enrollment target
170
Sites
France

Condition studied

Erosive osteoarthritis

Investigational medicinal product(s)

SODIUM CHLORIDE SOLUTION 0.9%SPECIAFOLDINE 5 mgcompriméMETOJECT 15 mg / 030 mlsolution injectable en stylo prérempli

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Structural damage is assessed using the Verbruggen-Veys score. The evolution of structural damage between M0 and M12, or worsening, of digital osteoarthritis of a joint will be defined by the change in stage of the Verbruggen-Veys score by at least one level

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2022-502362-24-00 on CTIS ↗ ← All trials in the EU